Osvaren (Magnesium Carbonate Heavy, Calcium Acetate)

Osvaren is a phosphate‑binding agent used in the management of disorders that involve elevated serum phosphate.

• Chronic kidney disease (CKD): helps lower the serum phosphate concentration.
• End‑stage renal disease (ESRD) on dialysis: assists in maintaining target phosphate levels.
• Hyperphosphatemia secondary to renal failure: reduces phosphate absorption from the gut.
• Post‑transplant hyperphosphatemia: supports phosphate control after kidney transplantation.
• Dietary phosphate overload: aids in limiting phosphate uptake from meals.

• Osvaren provides a source of magnesium and calcium ions that bind dietary phosphate in the gastrointestinal lumen, forming insoluble magnesium‑calcium phosphate complexes that are excreted in the feces. This reduces the amount of phosphate absorbed into the bloodstream, helping to maintain lower serum phosphate concentrations in patients with impaired renal excretion.

Osvaren may cause gastrointestinal and metabolic reactions, most of which are mild and reversible.

Common Side Effects

• Nausea: occasional mild nausea.
• Abdominal discomfort: cramping or bloating.
• Constipation: reduced bowel movements.
• Diarrhoea: loose stools.
• Metallic taste: transient metallic sensation in the mouth.

Serious or Rare Side Effects

• Hypermagnesemia: elevated magnesium levels, especially in patients with severe renal impairment.
• Hypercalcemia: excess calcium accumulation.
• Severe abdominal pain: persistent or worsening pain.
• Allergic reaction: rash, itching, or swelling.
• Electrolyte imbalance: significant shifts in calcium or magnesium balance.

When using Osvaren, consider the following safety measures:

• Renal function monitoring: assess serum phosphate, calcium and magnesium regularly.
• Electrolyte balance: watch for signs of hypercalcemia or hypermagnesemia.
• Concomitant phosphate binders: avoid simultaneous use with other oral phosphate binders without medical guidance.
• Gastrointestinal disorders: use cautiously in patients with bowel obstruction or severe constipation.
• Pregnancy and lactation: evaluate risk‑benefit ratio before prescribing.
• Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Osvaren can affect the absorption or activity of several co‑administered medicines.

Major Interactions (Avoid)

• Iron supplements: may reduce phosphate‑binder efficacy and vice versa.
• Tetracycline antibiotics: binding may lower antibiotic absorption.
• Oral bisphosphonates: concurrent use can impair bisphosphonate uptake.

Moderate Interactions (Monitor Closely)

• Calcium‑containing antacids: may increase calcium load.
• Vitamin D analogues: risk of hypercalcemia when combined.
• Loop diuretics: may exacerbate electrolyte shifts.
• Proton pump inhibitors: potential alteration of gastric pH affecting binder performance.
• Oral potassium supplements: monitor serum potassium levels.